How Many Genesis Healthcare, Inc. (NYSE:GEN)’s Analysts Are Bearish?

June 14, 2018 - By Darrin Black

Genesis Healthcare, Inc. (NYSE:GEN) Ratings Coverage

Among 3 analysts covering Genesis Healthcare (NYSE:GEN), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Genesis Healthcare had 3 analyst reports since March 19, 2018 according to SRatingsIntel. On Monday, March 19 the stock rating was maintained by Stephens with “Hold”. Cantor Fitzgerald maintained it with “Buy” rating and $700 target in Friday, May 11 report. Stifel Nicolaus maintained the shares of GEN in report on Tuesday, April 24 with “Hold” rating. Below is a list of Genesis Healthcare, Inc. (NYSE:GEN) latest ratings and price target changes.

11/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $7.0000 Maintain
24/04/2018 Broker: Stifel Nicolaus Rating: Hold New Target: $2.0000 Maintain
19/03/2018 Broker: Stephens Rating: Hold New Target: $2.0 Maintain

The stock increased 10.00% or $0.24 during the last trading session, reaching $2.64. About 1.20 million shares traded or 73.09% up from the average. Genesis Healthcare, Inc. (NYSE:GEN) has risen 5.21% since June 14, 2017 and is uptrending. It has underperformed by 7.36% the S&P500.

Genesis HealthCare, Inc., together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company has market cap of $420.94 million. The firm operates through three divisions: Inpatient Services, Rehabilitation Therapy Services, and All Other Services. It currently has negative earnings. It also provides a range of rehabilitation therapy services, including speech pathology, physical therapy, occupational therapy, and respiratory therapy.

More news for Genesis Healthcare, Inc. (NYSE:GEN) were recently published by: Globenewswire.com, which released: “Research Report Identifies Charter Communications, Banco Bilbao Viscaya Argentaria SA, Maxwell Technologies …” on June 14, 2018. Ocbj.com‘s article titled: “Sabra Sells 12 Facilities for $134M” and published on June 04, 2018 is yet another important article.

Genesis Healthcare, Inc. (NYSE:GEN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: